Fera

Celebrate the 12 Days of Dripcember with Daily Themes, Exclusive Events, and Amazing Creators

Retrieved on: 
Thursday, December 14, 2023

SAN FRANCISCO, Dec. 14, 2023 /PRNewswire/ -- This Dripcember, Drip Shop Live invites collectors and enthusiasts to the much-anticipated 12 Days of Dripcember. This unique live shopping event, tailored for the collectibles community, features daily themes, exclusive promotions, and a lineup of some of the most influential creators like Unlisted Leaf, Chumlee, and King Gary in the collectibles space. Each day features live streams brimming with unique collectibles and vibrant personalities.

Key Points: 
  • SAN FRANCISCO, Dec. 14, 2023 /PRNewswire/ -- This Dripcember, Drip Shop Live invites collectors and enthusiasts to the much-anticipated 12 Days of Dripcember.
  • Daily Themes and Exclusive Events:
    Dripcember is not just an event; it's a celebration of the collectibles community.
  • Every day in December, participants can enjoy a different theme, ranging from free shipping offers to special promo codes and exclusive events like Drops, Mystery Bags and more.
  • The 12 Days of Dripcember features a roster of renowned creators, each bringing their unique flair to the event:
    12/14: Danny Phantump's Phanny Packs giveaway, and TCGNation's Flash Fire Box Break.

LSL Pharma Group Announces Exclusive Distribution Agreement With Fera Pharmaceuticals to Alleviate Drug Shortage in U.S. Hospitals

Retrieved on: 
Wednesday, October 18, 2023

BOUCHERVILLE, Québec, Oct. 18, 2023 (GLOBE NEWSWIRE) -- LSL Pharma Group Inc. (TSXV: LSL), (the “Company” or “LSL Pharma Group”), a Canadian integrated pharmaceutical company, announced today that it has entered into an exclusive agreement with Fera Pharmaceuticals, LLC (“Fera”), a U.S. specialty pharmaceutical company, to provide Erythromycin ophthalmic ointment USP (5mg/g) for the treatment of newborns in U.S. hospitals.

Key Points: 
  • BOUCHERVILLE, Québec, Oct. 18, 2023 (GLOBE NEWSWIRE) -- LSL Pharma Group Inc. (TSXV: LSL), (the “Company” or “LSL Pharma Group”), a Canadian integrated pharmaceutical company, announced today that it has entered into an exclusive agreement with Fera Pharmaceuticals, LLC (“Fera”), a U.S. specialty pharmaceutical company, to provide Erythromycin ophthalmic ointment USP (5mg/g) for the treatment of newborns in U.S. hospitals.
  • The agreement essentially focuses on fulfilling the need in the one-gram tube market.
  • Under the terms of the agreement, LSL Pharma Group, via its manufacturing subsidiary Steri-Med Pharma Inc. (“Steri-Med”), could initially supply up to 25% of the four million doses required annually in the U.S. hospital market.
  • “LSL Pharma Group is pleased to respond to this urgent healthcare need by making our eye medication readily available to the U.S. market,” stated François Roberge, President and Chief Executive Officer of LSL Pharma Group.

Fera Pharmaceuticals Announces FDA Orphan Designation of Phospholine Iodide® for the Treatment of Stargardt Disease

Retrieved on: 
Tuesday, April 12, 2022

Fera is pleased to announce that FDA has granted Orphan Drug Designation for Phospholine Iodide (echothiophate iodide for ophthalmic solution) as a treatment for Stargardt disease.

Key Points: 
  • Fera is pleased to announce that FDA has granted Orphan Drug Designation for Phospholine Iodide (echothiophate iodide for ophthalmic solution) as a treatment for Stargardt disease.
  • Having only just recently acquired Phospholine Iodide from Pfizer in August, we are excited to work toward extending the utility of this medically important product.
  • Stargardt disease is an eye disease that causes vision loss in children and young adults.
  • In people with Stargardt disease, special light-sensing cells in the macula, called photoreceptors, die off.

Nicox’s Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA for Naproxcinod for the Treatment of Sickle Cell Disease

Retrieved on: 
Wednesday, March 2, 2022

Nicoxs Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA for Naproxcinod for the Treatment of Sickle Cell Disease

Key Points: 
  • Nicoxs Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA for Naproxcinod for the Treatment of Sickle Cell Disease
    Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, and Fera Pharmaceuticals, a privately-held, U.S. specialty pharmaceutical company, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Orphan Drug Designation for naproxcinod for the treatment of sickle cell disease, which affects an estimated 100,000 Americans.
  • We congratulate Fera on achieving Orphan Drug Designation for naproxcinod, which is a very important step in being able to develop this molecule as a potential treatment for sickle cell disease.
  • We are extremely pleased that the FDA granted Orphan Drug status for naproxcinod as it now allows us to continue our development for sickle cell disease with the benefits that come along with this designation.
  • The FDA Orphan Drug Designation program provides orphan status to drugs and biologics that are intended for the safe and effective treatment, diagnosis, or prevention of rare diseases that affect fewer than 200,000 people in the U.S.

Nicox First Half 2021 Financial Results and Business Update

Retrieved on: 
Monday, September 27, 2021

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today reported the financial results for Nicox SA and its subsidiaries (the Nicox Group) for the six months ending June 30, 2021 and provided an update on recent events as well as progress on key programs.

Key Points: 
  • Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today reported the financial results for Nicox SA and its subsidiaries (the Nicox Group) for the six months ending June 30, 2021 and provided an update on recent events as well as progress on key programs.
  • Net revenue1 for the first half of 2021 was 1.3 million (including 1.2 million in royalty revenue) versus 2.4 million (including 1.4 million in royalty revenue) for the first half of 2020.
  • Operating expenses for the first half of 2021 were 13.3 million compared to 10.2 million for the first half of 2020.
  • As of June 30, 2021, the Nicox Group had cash and cash equivalents of 36.5 million, as compared with 42.0 million at March 31, 2021 and 47.2 million at December 31, 2020.

Keeping Customers Connected: Suspension of Energy Service Disconnections Extended to September 30, 2021

Retrieved on: 
Tuesday, July 6, 2021

While the moratorium has been extended, other emergency customer protections put in place by the CPUC during the pandemic have expired.

Key Points: 
  • While the moratorium has been extended, other emergency customer protections put in place by the CPUC during the pandemic have expired.
  • Recertifications and Post-Enrollment Verifications for the California Alternate Rates for Energy (CARE) and Family Electric Rate Assistance (FERA) programs have resumed.
  • CARE/FERA customers whose program eligibility would have expired between March 4, 2020 and June 30, 2021 will be required to re-certify.
  • Customers whose program eligibility expired on or after July 1, 2021 will be required to recertify within 90 days.

Nicox Updates on Fera Pharmaceuticals’ Continuing Evaluation of Naproxcinod

Retrieved on: 
Friday, April 30, 2021

b'Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, and Fera Pharmaceuticals, a privately-held, U.S. specialty pharmaceutical company, today provided an update on Fera\xe2\x80\x99s evaluation of naproxcinod for future development.

Key Points: 
  • b'Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, and Fera Pharmaceuticals, a privately-held, U.S. specialty pharmaceutical company, today provided an update on Fera\xe2\x80\x99s evaluation of naproxcinod for future development.
  • Nicox and Fera entered into an agreement in December 2015, amended in September 2018 and December 2020, which granted Fera exclusive rights to develop and commercialize naproxcinod for the U.S. market.
  • A broad clinical package already exists for naproxcinod in osteoarthritis, including three phase 3 trials with over 2,700 patients.\nFera Pharmaceuticals is a privately held company.
  • Nicox disavows any obligation to correct or to update the information contained in analyst reports.\n'

Nicox’s Partner Fera Pharmaceuticals to Investigate Naproxcinod as Potential Covid-19 Adjuvant Treatment

Retrieved on: 
Friday, December 11, 2020

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, and Fera Pharmaceuticals, a privately-held, U.S. specialty pharmaceutical company, announced today that Fera will evaluate naproxcinod as a potential adjuvant treatment for patients with COVID-19 infection.

Key Points: 
  • Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, and Fera Pharmaceuticals, a privately-held, U.S. specialty pharmaceutical company, announced today that Fera will evaluate naproxcinod as a potential adjuvant treatment for patients with COVID-19 infection.
  • Nicox and Fera entered into an agreement in December 2015 which granted Fera exclusive rights to develop and commercialize naproxcinod for the U.S. market.
  • Nicox and Fera are amending their existing agreement to include COVID-19 as an indication, and Nicox will grant to Fera warrants1 to acquire 10,000 Nicox shares.
  • Once Fera has received the newly manufactured naproxcinod, they plan to initiate proof-of-concept pre-clinical tests in models of COVID-19 infection.